Literature DB >> 22550041

Depression and quality of life in monogenic compared to idiopathic, early-onset Parkinson's disease.

Meike Kasten1, Lena Kertelge, Vera Tadic, Norbert Brüggemann, Alexander Schmidt, Joyce van der Vegt, Hartwig Siebner, Carsten Buhmann, Rebekka Lencer, Kishore R Kumar, Katja Lohmann, Johann Hagenah, Christine Klein.   

Abstract

Quality of life (QoL) is decreased in PD and is linked with depression and anxiety. However, little is known about QoL in monogenic PD. Subjects with mutations in PD genes were recruited from ongoing family and genetic studies (manifesting carriers, n = 23; nonmanifesting carriers, n = 19). For comparison purposes, we included patients with idiopathic PD (IPD; n = 128; early onset, n = 38; late onset, n = 90), healthy controls (n = 127), and data on depressive symptoms of 144 patients with major depression (treated controls). Depression affected 31% of early-onset PD cases, 21% of late-onset cases, and 44% of manifesting carriers of mutations in PD genes, but was rare in the nonmanifesting carriers (7%) and healthy controls (5%). Subjects with Parkinson-associated depression reported fewer feelings of guilt or self-doubt than treated controls, but the occurrence of suicidal ideation was associated with severity of depression only. Social phobia (P = 0.018) and agoraphobia (P = 0.059) were more common in manifesting carriers than in any other group. QoL was decreased in the Parkinson groups, particularly in the early-onset cases (P < 0.001), and QoL correlated with depression in all analyses. In our study, monogenic and IPD cases were comparable in QoL and depression characteristics. The QoL and, possibly, overall prognosis of all PD patients can be improved by appropriate attention and treatment for depression, sleep impairments, and anxiety, even if the treatment of the motor problems cannot be further optimized.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 22550041     DOI: 10.1002/mds.24999

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.

Authors:  Chiara Fabbri; Concetta Crisafulli; Raffaella Calati; Diego Albani; Gianluigi Forloni; Marco Calabrò; Rosalba Martines; Siegfried Kasper; Joseph Zohar; Alzbeta Juven-Wetzler; Daniel Souery; Stuart Montgomery; Julien Mendlewicz; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-04       Impact factor: 5.270

2.  Analysis of blood-based gene expression in idiopathic Parkinson disease.

Authors:  Ron Shamir; Christine Klein; David Amar; Eva-Juliane Vollstedt; Michael Bonin; Marija Usenovic; Yvette C Wong; Ales Maver; Sven Poths; Hershel Safer; Jean-Christophe Corvol; Suzanne Lesage; Ofer Lavi; Günther Deuschl; Gregor Kuhlenbaeumer; Heike Pawlack; Igor Ulitsky; Meike Kasten; Olaf Riess; Alexis Brice; Borut Peterlin; Dimitri Krainc
Journal:  Neurology       Date:  2017-09-15       Impact factor: 9.910

Review 3.  A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.

Authors:  Lama M Chahine; Amy W Amara; Aleksandar Videnovic
Journal:  Sleep Med Rev       Date:  2016-08-31       Impact factor: 11.609

4.  Suicide in Parkinson's disease.

Authors:  Melissa Deanna Shepard; Kate Perepezko; Martijn P G Broen; Jared Thomas Hinkle; Ankur Butala; Kelly A Mills; Julie Nanavati; Nicole Mercado Fischer; Paul Nestadt; Gregory Pontone
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-01-19       Impact factor: 10.154

5.  Qualitative Characteristics of Depression in Parkinson's Patients and Controls.

Authors:  Cleo Kritzinger; Eva-Juliane Vollstedt; Katja Hückelheim; Anne Lorwin; Julia Graf; Sinem Tunc; Christine Klein; Meike Kasten
Journal:  Behav Neurol       Date:  2015-08-16       Impact factor: 3.342

6.  Quality of life in Parkinson's disease: A systematic review and meta-analysis of comparative studies.

Authors:  Na Zhao; Yuan Yang; Ling Zhang; Qinge Zhang; Lloyd Balbuena; Gabor S Ungvari; Yu-Feng Zang; Yu-Tao Xiang
Journal:  CNS Neurosci Ther       Date:  2020-12-28       Impact factor: 5.243

7.  Heterogeneous Determinants of Quality of Life in Different Phenotypes of Parkinson's Disease.

Authors:  Seyed-Mohammad Fereshtehnejad; Mahdiyeh Shafieesabet; Farzaneh Farhadi; Hasti Hadizadeh; Arash Rahmani; Nader Naderi; Dena Khaefpanah; Gholam Ali Shahidi; Ahmad Delbari; Johan Lökk
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

8.  Health-related quality of life in Parkinson's disease patients in northeastern Sicily, Italy: (An ecological perspective).

Authors:  Letteria Spadaro; Lilla Bonanno; Giuseppe Di Lorenzo; Placido Bramanti; Silvia Marino
Journal:  Neural Regen Res       Date:  2013-06-15       Impact factor: 5.135

9.  Cognitive behavioral therapy for insomnia in Parkinson's disease: a case series.

Authors:  Meghan Humbert; James Findley; Maria Hernandez-Con; Lana M Chahine
Journal:  NPJ Parkinsons Dis       Date:  2017-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.